Design, synthesis and structure of peptides and proteins news

<p>The graphic shows a new class of prolyl oligopeptidase (POP) inhibitor. The inhibitor is able to reach the brain and bind to the POP protein, In yellow/red, the reactive group of the inhibitor that bind to the catalytic site of the protein (S Guardiola)</p>
17 May 2018

For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.

Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.

<p>Natàlia Carulla's team studies the associations of beta-amyloid. In the microscopy image, beta-amyloid clusters are observed in in vitro samples. (Bernat Serra-Vidal, IRB Barcelona)</p>
20 Apr 2018

Europa Press, El Economista, Technology Networks, News Medical, among other national and international media, have published an article about a study headed by IRB Barcelona that provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.

Link to Europa Press

Link to...

<p>Illustrative image of how scientists have deciphered the covalent nature of beta-amyloid dimers, an article published in Analytical Chemistry. Authors: Marina Gay, IRB Barcelona, and Lorena Markovich</p>
17 Apr 2018

A study headed by IRB Barcelona provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.

Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.

<p>Ernest Giralt</p>
14 Feb 2018

The Meet Our Scientists series presents Ernest Giralt, doctor of chemical sciences, who is the head of the Peptides and Proteins laboratory at IRB Barcelona.

In the video "The power of medicinal chemistry", Giralt highlights his interest in deciphering the language used by proteins to interact with each other.

<p>Image: Aydinlik</p>
23 Jan 2018

The Turkish media Aydinlik has published an article about the possibility of using poisons as medicine. The article includes a reference to the research on the use of bee venom as a strategy to selectively eliminate cancer cells, led by Ernest Giralt, leader of the Laboratory of Design, Synthesis and Structure of Peptides and Proteins of IRB Barcelona.

Link to Aydinlik

<p>Detail of one millimeter of a mouse brain. In green, capillaries that form part of the blood-brain barrier; in red, molecules attached to the shuttle patented by IRB Barcelona have managed to cross the barrier and reach the brain. (B Oller, IRB)</p>
9 Nov 2017

IRB Barcelona researcher Meritxell Teixidó has participated in the report "Menudes Teràpies" on the programme Quèquicom, broadcasted by Canal 33, There she talked about the advances made by the Design, Synthesis and Structure of Peptides and Proteins Lab, led by Ernest Giralt, regarding drugs with the capacity to overcome the blood-brain barrier and reach the brain.

Link to Menudes Teràpies

Link to additional clip

3 Oct 2017

The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.

29 Sep 2017

The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.

The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.

<p>Teresa Tarragó is co-founder of IProteos, an IRB Barcelona spinf-off (D. Portales)</p>
25 Sep 2017

Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.

Link to Innovaspain.com

<p>Teresa Tarragó, CEO and co-founder of Iproteos</p>
23 Sep 2017

Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.

Link to Agencia SINC